Results of a Second Year of Therapy with the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty

Background. Gonadotropin releasing hormone analogs (GnRHas) are standard of care for central precocious puberty (CPP). The histrelin subcutaneous implant is safe and effective in the treatment of CPP for one year. Objective. The study evaluates a second year of therapy in children with CPP who recei...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rahhal, Samar, Clarke, William L., Kletter, Gad B., Lee, Peter A., Neely, E. Kirk, Reiter, Edward O., Saenger, Paul, Shulman, Dorothy, Silverman, Lawrence, Eugster, Erica A.
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2009
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2777002/
https://ncbi.nlm.nih.gov/pubmed/19956699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2009/812517
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados